Results 71 to 80 of about 6,218 (156)

Nirmatrelvir/Ritonavir Efficacy in Immunocompetent Patients with Confirmed Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2: An Updated Systematic Review and Meta-analysis. [PDF]

J Res Pharm Pract
Khani E, Afsharirad H, Yadegari AT, Zarezadeh M, Asham H, Bannazadeh-Baghi H, Entezari-Maleki T.   +6 more
europepmc   +1 more source

Resistance to nirmatrelvir due to mutations in the Mpro in the subvariants of SARS-CoV-2 Omicron: Another concern?

Molecular Therapy: Nucleic Acids, 2023
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, Sang-Soo Lee, Chiranjib Chakraborty   +4 more
doaj   +1 more source

Patient Characteristics and Healthcare Resource Use among Patients With COVID-19 Receiving Treatment with Nirmatrelvir/Ritonavir (PAXLOVID™) in the Kingdom of Saudi Arabia. [PDF]

Pulm Ther
Alraddadi BM, Almaghrabi RS, Bosaeed M, Kamal M, Hassanien A, Hammam H, Zanotti G, Ikizler BK, d'Hellencourt FL, Spinardi JR, Wang L, Kyaw MH.   +11 more
europepmc   +1 more source

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir. [PDF]

J Virol
Chen L, Su H, Shang W, Nie T, Kuang W, Wang C, Shao Q, Zhang L, Liu W, Xu Y, Zhang Y.   +10 more
europepmc   +1 more source

A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection. [PDF]

J Antimicrob Chemother
Khoo SH, FitzGerald R, Edwards CJ, Ahmad S, Saunders G, Else LJ, Shaw V, Mozgunov P, Northey J, Dickinson L, Knox E, Buadi A, Hale C, Reynolds HE, Middleton C, Bullock K, Walker L, Walker L, Tetlow M, Lyon R, Gibney J, Amara A, Greenhalf W, Burdon A, Dixon J, Jaki T, Chiong J, Lalloo DG, Owen A, Jacobs M, Fletcher T, Griffiths G, AGILE CST-8 study group .   +32 more
europepmc   +1 more source

Severe HCoV-OC43 Pneumonia in a 25-Year-Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation. [PDF]

Clin Respir J
Zhang M, Tang T, Zheng M, Luo M, Xu Z, Wang G.   +5 more
europepmc   +1 more source

Design, Synthesis, and Evaluation of Novel Thiazole-Based Peptidomimetic Compounds as Potent SARS-CoV-2 Main Protease Covalent Inhibitors. [PDF]

ACS Infect Dis
Yin W, Kong WP, Leung SL, Liang Z, Chen YW, Wong KY.   +5 more
europepmc   +1 more source

Bio-inspired chemometric methods for simultaneous UV spectrophotometric determination of molnupiravir, nirmatrelvir, and favipiravir in pharmaceutical formulations and environmental samples. [PDF]

Sci Rep
Abdelzaher AM, Al Kamaly O, Rahman MAA.
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID-19 and Severe Renal Impairment. [PDF]

Clin Pharmacol Ther
Gerhart J, Bramson CR, Goulding M, Shi H, Oladoyinbo O, Chan PLS, Chime S, Hammond J.   +7 more
europepmc   +1 more source

Oral Nirmatrelvir-Ritonavir for Covid-19 in Higher-Risk Outpatients. [PDF]

N Engl J Med
Butler CC, Pinto AD, Harris V, Holmes J, Rahman NM, Cureton L, Hayward G, Richards DB, Lowe DM, Standing JF, Breuer J, Hood K, Png ME, Petrou S, Dorward J, Patel MG, Thomas NPB, Evans P, Hart ND, Jani BD, Hosseini B, Murthy S, McBrien K, Condon A, McDonald EG, Daley P, Greiver M, da Costa BR, Selby P, Jüni P, Lee TC, Shi H, Detry MA, Saunders CT, Fitzgerald M, Berry NS, Saville BR, Khoo SH, Nguyen-Van-Tam JS, Hobbs FDR, Yu LM, Little P, PANORAMIC Trial and CanTreatCOVID Trial Collaborative Groups.   +42 more
europepmc   +1 more source